Unlocking the potential of
genomic medicine

News Release

View printer-friendly version << Back
Medgenics to Present at 27th Annual Piper Jaffray Healthcare Conference

PHILADELPHIA, Nov. 25, 2015 (GLOBE NEWSWIRE) -- Medgenics, Inc.(NYSE MKT:MDGN), today announced that Michael Cola, President and CEO, will participate in a fireside chat discussion at the 27th Annual Piper Jaffray Healthcare Conference in New York.

The event will take place at 3:30 p.m. ET on Wednesday, December 2, 2015 at the New York Palace Hotel. A live webcast of the presentation can be accessed under "Presentations" in the Investors section of the Company's website at www.medgenics.com or you may use the link: http://edge.media-server.com/m/p/ypm42agv.  

About Medgenics, Inc.

Medgenics is dedicated to unlocking the potential of genomic medicine to identify and treat patients with life-altering conditions. Its efforts, including its internal research and development and ongoing sponsored research and licensing agreements with a well-respected pediatric academic medical center, give Medgenics the ability to focus on the underlying genetic pathway of pediatric diseases with the goal of finding therapeutic solutions for subpopulations of both children and adults living with rare and other difficult-to-treat diseases. For more information, visit the Company's website at www.medgenics.com.

CONTACT: Medgenics, Inc.John Leamanjohn.leaman@medgenics.com

         Brian PiperBrian.piper@medgenics.com

         Stern Investor Relations
         Beth DelGiacco
         212-362-1200
         Beth@sternir.com

Medgenics, Inc. logo

Medgenics, Inc.